AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1346539 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamox (acetazolamide)
Number of subjects: 0
Study 1346539 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 6345176 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprofylline
Number of subjects: 6
Study 6345176 — intervention group
Group type: COMPARATOR
Intervention: Theophylline
Number of subjects: 6
Study 28872380 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity training (HA-L)
Number of subjects: 19
Study 28872380 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity training (HA-H)
Number of subjects: 19
Study 28872380 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual training in thermoneutral conditions)
Number of subjects: 19
Study 27161956 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 41
Study 27161956 — intervention group
Group type: COMPARATOR
Intervention: Control (reading newspapers or watching television)
Number of subjects: 41
Study 25005782 — intervention group
Group type: EXPERIMENTAL
Intervention: WPH + CHO supplementation with ECC resistance training
Number of subjects: 24
Study 25005782 — intervention group
Group type: COMPARATOR
Intervention: CHO supplementation with ECC resistance training
Number of subjects: 24
Study 25005782 — intervention group
Group type: EXPERIMENTAL
Intervention: ECC resistance training
Number of subjects: 24
Study 25005782 — intervention group
Group type: EXPERIMENTAL
Intervention: CONC resistance training
Number of subjects: 24
Study 25005782 — intervention group
Group type: EXPERIMENTAL
Intervention: Both WPH + CHO and CHO supplementation
Number of subjects: 24
Study 21374756 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic percutaneous endoscopic gastrostomy (PEG)
Number of subjects: 134
Study 21374756 — intervention group
Group type: COMPARATOR
Intervention: Clinical praxis (control group)
Number of subjects: 134
Study 20868961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapleson D circuit
Number of subjects: 18
Study 20868961 — intervention group
Group type: COMPARATOR
Intervention: bag‐valve‐mask device
Number of subjects: 18
Study 18651608 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg nabumetone tablet formulation
Number of subjects: 12
Study 17121035 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingre Yulin Decoction (QYD)
Number of subjects: 60
Study 17121035 — intervention group
Group type: COMPARATOR
Intervention: Antibiotic plus vitamin E (Control)
Number of subjects: 60
Study 12110823 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0
Study 12110823 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10036560 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education intervention
Number of subjects: 0
Study 7750315 — intervention group
Group type: EXPERIMENTAL
Intervention: Leukocyte specific filter
Number of subjects: 32
Study 7750315 — intervention group
Group type: COMPARATOR
Intervention: Standard blood filter
Number of subjects: 32
Study 1369947 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute stage of the disease
Number of subjects: 35
Study 1369947 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery period
Number of subjects: 35
Study 1369947 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study 6996538 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantomography
Number of subjects: 17
Study 6996538 — intervention group
Group type: COMPARATOR
Intervention: Standard 'four view' mandibular series
Number of subjects: 17
Study 31519364 — intervention group
Group type: EXPERIMENTAL
Intervention: Video‐assisted thoracoscopic surgery (VATS)
Number of subjects: 41
Study 31519364 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural fibrinolytic therapy (IFT)
Number of subjects: 41
Study 31519364 — intervention group
Group type: COMPARATOR
Intervention: VATS
Number of subjects: 41
Study 31519364 — intervention group
Group type: COMPARATOR
Intervention: IFT
Number of subjects: 41
Study 30806130 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed pure tones sound therapy
Number of subjects: 0
Study 30806130 — intervention group
Group type: COMPARATOR
Intervention: Broad band noise (BBN) sound therapy
Number of subjects: 0
Study 28831695 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplest model for insulin pharmacokinetics
Number of subjects: 0
Study 28831695 — intervention group
Group type: EXPERIMENTAL
Intervention: Models with increasing complexity
Number of subjects: 0
Study 28831695 — intervention group
Group type: EXPERIMENTAL
Intervention: Most complex models
Number of subjects: 0
Study 28831695 — intervention group
Group type: EXPERIMENTAL
Intervention: Best model with two linear subcutaneous compartments
Number of subjects: 0
Study 26425555 — intervention group
Group type: EXPERIMENTAL
Intervention: TCA haplotype (rs12483428-rs987195-rs4817027)
Number of subjects: 538
Study 26425555 — intervention group
Group type: EXPERIMENTAL
Intervention: CC haplotype (rs969885-rs987195)
Number of subjects: 538
Study 26425555 — intervention group
Group type: EXPERIMENTAL
Intervention: AA genotype at rs4817027
Number of subjects: 538
Study 26425555 — intervention group
Group type: EXPERIMENTAL
Intervention: CG haplotype (rs987195-rs969885)
Number of subjects: 538
Study 26425555 — intervention group
Group type: EXPERIMENTAL
Intervention: Copy number variants of the MIR155HG/miR-155 gene
Number of subjects: 538
Study 23657930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger powder
Number of subjects: 100
Study 23657930 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan
Number of subjects: 100
Study 19681940 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading of two bar‐splinted SLActive implants with an implant‐retained mandibular overdenture
Number of subjects: 124
Study 19301135 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention delivered at training sites in collaboration with unions.
Number of subjects: 1213
Study 17534806 — intervention group
Group type: EXPERIMENTAL
Intervention: One drop of cyclopentolate 1%
Number of subjects: 96
Study 17534806 — intervention group
Group type: EXPERIMENTAL
Intervention: Two drops of cyclopentolate 1%
Number of subjects: 96
Study 17534806 — intervention group
Group type: EXPERIMENTAL
Intervention: Three drops of cyclopentolate 1%
Number of subjects: 96
Study 14745567 — intervention group
Group type: EXPERIMENTAL
Intervention: Shed blood collection and reinfusion using SureTrans System (Group A, n=194)
Number of subjects: 365
Study 14745567 — intervention group
Group type: COMPARATOR
Intervention: No shed blood collection and reinfusion (Control Group B, n=171)
Number of subjects: 365
Study 11443604 — intervention group
Group type: EXPERIMENTAL
Intervention: 18 grays (Gy) of cranial radiation therapy
Number of subjects: 201
Study 9856729 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane
Number of subjects: 2408
Study 8576295 — intervention group
Group type: EXPERIMENTAL
Intervention: mebeverine plain 135 mg, two capsules t.i.d.
Number of subjects: 60
Study 8576295 — intervention group
Group type: EXPERIMENTAL
Intervention: mebeverine sustained release 200 mg (SR), two capsules b.i.d.
Number of subjects: 60
Study 8576295 — intervention group
Group type: COMPARATOR
Intervention: Both formulations (mebeverine plain and mebeverine SR)
Number of subjects: 60
Study 8576295 — intervention group
Group type: EXPERIMENTAL
Intervention: mebeverine plain
Number of subjects: 60
Study 8576295 — intervention group
Group type: EXPERIMENTAL
Intervention: mebeverine SR
Number of subjects: 60
Study 8576295 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 60
Study 2142109 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol (600 mg a day)
Number of subjects: 0
Study 2142109 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose medroxyprogesterone acetate (MPA; 100 mg a day)
Number of subjects: 0
Study 2142109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 357069 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fenmetozole
Number of subjects: 8
Study 357069 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 200 mg fenmetozole and 50 ml/70 kg ethanol
Number of subjects: 8
Study 357069 — intervention group
Group type: COMPARATOR
Intervention: None (control for fenmetozole)
Number of subjects: 8
Study 357069 — intervention group
Group type: COMPARATOR
Intervention: None (control for ethanol)
Number of subjects: 8
Study 31136652 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (trigram character-recognition trials over 4 consecutive days)
Number of subjects: 26
Study 31136652 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 26
Study 31136652 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group
Number of subjects: 26
Study 27177885 — intervention group
Group type: EXPERIMENTAL
Intervention: Unadjusted cluster-level analysis
Number of subjects: 0
Study 27177885 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline covariate adjusted cluster-level analysis
Number of subjects: 0
Study 27177885 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear mixed model analysis
Number of subjects: 0
Study 27177885 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster mean imputation
Number of subjects: 0
Study 27177885 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple imputation
Number of subjects: 0
Study 25740700 — intervention group
Group type: EXPERIMENTAL
Intervention: Tube current limitation at 210 mA
Number of subjects: 118
Study 25740700 — intervention group
Group type: COMPARATOR
Intervention: Tube current limitation at 450 mA
Number of subjects: 118
Study 25740700 — intervention group
Group type: COMPARATOR
Intervention: No limitation
Number of subjects: 118
Study 23084438 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone lactation counselling (n=179)
Number of subjects: 357
Study 23084438 — intervention group
Group type: COMPARATOR
Intervention: Current conventional care of postnatal breastfeeding support (Control group, n=178)
Number of subjects: 357
Study 23084438 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=178)
Number of subjects: 357
Study 20970833 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium XR 60 mg
Number of subjects: 176
Study 20970833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 20970833 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium XR
Number of subjects: 176
Study 19752581 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg/day of ARA-enriched triglyceride (SUNTGA40S; containing 240 mg ARA)
Number of subjects: 25
Study 19752581 — intervention group
Group type: COMPARATOR
Intervention: Olive oil capsules (inactive placebo)
Number of subjects: 25
Study 16648511 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic trolamine emulsion
Number of subjects: 547
Study 16648511 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventional trolamine emulsion
Number of subjects: 547
Study 16648511 — intervention group
Group type: COMPARATOR
Intervention: Institutional preference
Number of subjects: 547
Study 12924804 — intervention group
Group type: EXPERIMENTAL
Intervention: Neomune
Number of subjects: 36
Study 10570589 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement
Number of subjects: 40
Study 10570589 — intervention group
Group type: COMPARATOR
Intervention: Amalgam
Number of subjects: 40
Study 8891660 — intervention group
Group type: EXPERIMENTAL
Intervention: L-dopa
Number of subjects: 11
Study 8891660 — intervention group
Group type: COMPARATOR
Intervention: Control (pre-L-dopa administration)
Number of subjects: 11
Study 1676392 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg nizatidine
Number of subjects: 12
Study 1676392 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine
Number of subjects: 12
Study 1676392 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1676392 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol alone
Number of subjects: 12
Study 1676392 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol with nizatidine
Number of subjects: 12
Study 1676392 — intervention group
Group type: EXPERIMENTAL
Intervention: Nizatidine
Number of subjects: 12
Study 6837464 — intervention group
Group type: EXPERIMENTAL
Intervention: Iohexol
Number of subjects: 50
Study 6837464 — intervention group
Group type: COMPARATOR
Intervention: Sodium meglumine diatrizoate (Renografin‐76)
Number of subjects: 50
Study 4027125 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (2.5 g) administered 1 h after mefenamic acid
Number of subjects: 9
Study 4027125 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated charcoal (2.5 g) and hyoscine butylbromide (20 mg) administered after mefenamic acid
Number of subjects: 9
Study 4027125 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine butylbromide (20 mg) administered immediately after mefenamic acid
Number of subjects: 9
Study 28834955 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple ART
Number of subjects: 289
Study 28834955 — intervention group
Group type: COMPARATOR
Intervention: Short course ZDV
Number of subjects: 289
Study 27859666 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH) for 12 weeks
Number of subjects: 86
Study 27859666 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATM) for 12 weeks
Number of subjects: 86
Study 27859666 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH) and Atomoxetine (ATM)
Number of subjects: 86
Study 25159085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (5,000 lx)
Number of subjects: 125
Study 25159085 — intervention group
Group type: COMPARATOR
Intervention: Placebo control (230 lx)
Number of subjects: 125
Study 22729470 — intervention group
Group type: EXPERIMENTAL
Intervention: Structum (500 mg twice daily)
Number of subjects: 43
Study 22729470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 20507203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Internet
Number of subjects: 38
Study 20507203 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Print
Number of subjects: 38
Study 20507203 — intervention group
Group type: COMPARATOR
Intervention: Standard Internet
Number of subjects: 38
Study 20507203 — intervention group
Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 38
Study 18451114 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg iv during induction of anesthesia
Number of subjects: 94
Study 18451114 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 2 mg iv approximately 30 min before the end of surgery
Number of subjects: 94
Study 18451114 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 2 mg iv (both groups)
Number of subjects: 94
Study 16416368 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-enriched artificial liquid diet (20 nonprotein kcal/kg per day) plus normal meals (group B, n = 12)
Number of subjects: 23
Study 16416368 — intervention group
Group type: COMPARATOR
Intervention: Conventional diet supplying 35 nonprotein kcal and 1.1 g of protein/kg per day (group A, n = 11)
Number of subjects: 23
Study 14569405 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP supplemented formula (0.5 g/100 g fat linoleic acid metabolites, 0.8 g/100 g fat alpha‐linolenic acid metabolites)
Number of subjects: 29
Study 14569405 — intervention group
Group type: COMPARATOR
Intervention: Formula devoid of LCP
Number of subjects: 29
Study 14569405 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP supplemented formula
Number of subjects: 29
Study 14569405 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP supplemented formula and formula devoid of LCP
Number of subjects: 29
Study 10453581 — intervention group
Group type: EXPERIMENTAL
Intervention: Yu Cong Tang (TCM decoction)
Number of subjects: 0
Study 8917256 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting after PTCA
Number of subjects: 119
Study 8917256 — intervention group
Group type: COMPARATOR
Intervention: PTCA only (Control)
Number of subjects: 119
Study 1886483 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 18
Study 1886483 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study 6352884 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin injection 30 to 60 minutes before breakfast
Number of subjects: 23
Study 6352884 — intervention group
Group type: COMPARATOR
Intervention: Insulin injection 5 minutes prior to breakfast
Number of subjects: 23
Study 31665074 — intervention group
Group type: EXPERIMENTAL
Intervention: EASE intervention
Number of subjects: 0
Study 31665074 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29851415 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating β cell‐reactive CD8+ T cell subsets (specifically CD57+ effector memory CD8+ T cells)
Number of subjects: 0
Study 29851415 — intervention group
Group type: EXPERIMENTAL
Intervention: Autoreactive CD57+ effector memory CD8+ T cells
Number of subjects: 0
Study 29851415 — intervention group
Group type: EXPERIMENTAL
Intervention: Network association modeling of β cell‐reactive CD57+ effector memory CD8+ T cell subsets
Number of subjects: 0
Study 27271658 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration glucose solution (250 mL containing 50% glucose)
Number of subjects: 0
Study 27271658 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral supplementation plus high-concentration glucose solution
Number of subjects: 0
Study 27271658 — intervention group
Group type: EXPERIMENTAL
Intervention: 8.5% amino acids solution
Number of subjects: 0
Study 27271658 — intervention group
Group type: COMPARATOR
Intervention: Control group (oral supplementation only)
Number of subjects: 0
Study 24297972 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based multilevel intervention
Number of subjects: 2016
Study 24297972 — intervention group
Group type: COMPARATOR
Intervention: Comparison area
Number of subjects: 2016
Study 22782542 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 0
Study 22782542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 0
Study 22782542 — intervention group
Group type: COMPARATOR
Intervention: Control (Neutral and Positive anticipation)
Number of subjects: 0
Study 18987358 — intervention group
Group type: EXPERIMENTAL
Intervention: lenalidomide 10 mg/day
Number of subjects: 47
Study 17693914 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation plus medicated bronchoalveolar lavage
Number of subjects: 20
Study 17693914 — intervention group
Group type: COMPARATOR
Intervention: Volume-controlled ventilation and bronchosuction
Number of subjects: 20
Study 16163098 — intervention group
Group type: EXPERIMENTAL
Intervention: Infiltration solutions at body temperature (37 degrees C)
Number of subjects: 30
Study 16163098 — intervention group
Group type: COMPARATOR
Intervention: Infiltration solutions at room temperature (24 degrees C)
Number of subjects: 30
Study 12412978 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg salmeterol
Number of subjects: 20
Study 12412978 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg salbutamol
Number of subjects: 20
Study 10472853 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 1 mg with norethindrone acetate 0.1 mg
Number of subjects: 1176
Study 10472853 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 1 mg with norethindrone acetate 0.25 mg
Number of subjects: 1176
Study 10472853 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 1 mg with norethindrone acetate 0.5 mg
Number of subjects: 1176
Study 10472853 — intervention group
Group type: COMPARATOR
Intervention: E2 1 mg (unopposed)
Number of subjects: 1176
Study 9087885 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment suggested by the trained ART (N = 21)
Number of subjects: 211
Study 9087885 — intervention group
Group type: COMPARATOR
Intervention: Consensus of two senior psychiatrists (N = 33)
Number of subjects: 211
Study 9087885 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment suggested by ART
Number of subjects: 211
Study 1846790 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichloroacetate (50 mg/kg body weight)
Number of subjects: 10
Study 1846790 — intervention group
Group type: COMPARATOR
Intervention: Sodium bicarbonate (1.5 mmol/kg body weight)
Number of subjects: 10
Study 6824557 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin
Number of subjects: 0
Study 6824557 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 0
Study 6824557 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31862249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine 0.7 mg/kg per day
Number of subjects: 119
Study 31862249 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenfluramine 0.2 mg/kg per day
Number of subjects: 119
Study 31862249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study 29921734 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous epoetin alfa-epbx
Number of subjects: 612
Study 29921734 — intervention group
Group type: COMPARATOR
Intervention: Intravenous epoetin alfa
Number of subjects: 612
Study 27438078 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 180
Study 27438078 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study 24925713 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid-enriched fish oil (600 mg daily)
Number of subjects: 173
Study 24925713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 22250633 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupuncture (weekly for 10 weeks)
Number of subjects: 60
Study 22250633 — intervention group
Group type: COMPARATOR
Intervention: 0.1% tretinoin ointment (topically for 10 weeks)
Number of subjects: 60
Study 20381161 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 30
Study 20381161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 18559351 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Supreme (SLMA)
Number of subjects: 36
Study 18559351 — intervention group
Group type: COMPARATOR
Intervention: LMA-Proseal (PLMA)
Number of subjects: 36
Study 15921786 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-min test
Number of subjects: 90
Study 15921786 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-min test
Number of subjects: 90